Roche’s Avastin Rejected by U.K. for Use in Breast Cancer

Roche Holding AG’s Avastin doesn’t meet cost criteria for extending the lives of breast-cancer patients when combined with the chemotherapy drug capecitabine, and shouldn’t be used as a first-line treatment, the U.K. medical-spending regulator said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.